|
Initial analyses of a phase I/II trial of durvalumab (D) plus tremelimumab (T) and stereotactic body radiotherapy (SBRT) for oligometastatic head and neck carcinoma. |
| |
|
Honoraria - Bristol-Myers Squibb |
Research Funding - Varian Medical Systems |
| |
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Medarex; Shire; Taiho Pharmaceutical |
Speakers' Bureau - Taiho Pharmaceutical |
Research Funding - Bristol-Myers Squibb/Medarex (Inst) |
| |
|
Consulting or Advisory Role - Bristol-Myers Squibb |
| |
|
Honoraria - Adlai Nortye; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Novartis; Pfizer |
Consulting or Advisory Role - Ipsen; Merck; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
| |
|
Employment - London Health Sciences Centre (LHSC) |
Patents, Royalties, Other Intellectual Property - US Patent: A Method for Analyzing a Three-Dimensional Computed Tomography Image, United States Patent Application No. 61/896349 (not licensed, no commercial or financial impact) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb |
Research Funding - AstraZeneca; Bristol-Myers Squibb |
Travel, Accommodations, Expenses - AstraZeneca |